A phase 1 study of IO-202, an antibody targeting LILRB4, in patients with monocytic differentiation AML and CMML

TAP Partner
Project Term: March 5, 2021 - TBD
In March 2021, LLS made an equity investment in Immune-Onc Therapeutics to support the "Phase 1 Clinical Development of IO-202, An Antibody Targeting LILRB4, for the Treatment of AML with Monocytic Differentiation and CMML." The company’s work builds on early research by Chengcheng (Alec) Zhang, Ph.D. at the University of Texas Southwestern Medical Center that was also funded by LLS grants. The lead candidate, called IO-202, a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4), has entered a phase 1 clinical trial for the treatment of advanced acute myeloid leukemia and chronic myelomonocytic leukemia.
For additional information, please visit https://lls.org/therapy-acceleration-program-portfolio